Stereotactic Body Radiotherapy for Early-stage Non–small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis

摘要

Stereotactic body radiotherapy (SBRT) for early-stage non–small-cell lung cancer use is evolving, with implementation in a rising geriatric oncologic population. Our study investigated the use of SBRT for non–small-cell lung cancer in 58 consecutive patients ≥ 80 years old at 4 academic centers. SBRT was well-tolerated with expected toxicity rates, excellent disease-specific outcomes, and patients with higher performance status deriving the greatest benefit.BackgroundStereotactic body radiotherapy (SBRT) is the standard of care for medically inoperable early-stage non– small-cell lung cancer. Despite the limited number of octogenarians and nonagenarians on trials of SBRT, its use is increasingly being offered in these patients, given the aging cancer population, medical fragility, or patient preference. Our purpose was to investigate the efficacy, safety, and survival of patients ≥80 years old treated with definitive lung SBRT.